AG真人官方

The Schedule 13G filed on 3 July 2025 reveals that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively own 153,219 Bone Biologics Corporation (BBLG) common shares, equal to 9.99 % of the class. The position consists of 148,500 issued shares and 4,791 shares underlying Intracoastal Warrant 2; all voting and dispositive power is shared among the three reporting persons.

The stake originates from a Securities Purchase Agreement signed on 27 June 2025, under which the Company issued 60,000 shares and seven separate warrants to Intracoastal. Each warrant carries an ownership 鈥渂locker鈥� that prevents exercise if the group鈥檚 beneficial ownership would exceed 9.99 % (or 4.99 % for several smaller warrants). Because of these blockers the group remains below the 10 % threshold required for Section 16 reporting.

Without the blocker provisions, the reporting group could control up to 821,294 shares immediately after the SPA and 719,794 shares as of 3 July 2025鈥攎ore than 1.3脳 the 545,260 shares outstanding on 20 June 2025鈥攊ndicating significant potential dilution for existing holders if the warrants become exercisable.

The certification section states the securities were not acquired to influence control of the issuer. Nonetheless, investors should monitor (1) the pace of warrant exercises, (2) any amendments to blocker thresholds, and (3) future Schedule 13D/G updates that could signal a change in intent or ownership.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has filed a Rule 424(b)(5) prospectus supplement establishing a US$50 million at-the-market (ATM) equity program through A.G.P./Alliance Global Partners. Under the July 3 2025 Sales Agreement, A.G.P. will act as sales agent on a best-efforts basis and receive a 3.0% commission on gross proceeds. No minimum drawdown is required and proceeds will not be placed in escrow.

The facility allows Tevogen to issue primary common shares (par $0.0001) from time to time at prevailing market prices. At the July 2 2025 closing price of US$1.25, management illustrates a scenario in which up to 40.0 million new shares could be issued, increasing basic shares outstanding from 184.4 million to 224.4 million (鈮�22% dilution).

Use of proceeds is intentionally broad: working capital, R&D (including ExacTcell鈩� and Tevogen.AI initiatives), capital expenditures, debt repayment, M&A, and other general corporate purposes. The company retains full discretion over timing and sizing of individual placements.

Balance-sheet impact & dilution. As of March 31 2025 Tevogen reported negative net tangible book value (NTBV) of US$(7.7)m, or US$(0.04) per share. Assuming the full US$50 million raise at US$1.25 per share (less 3% fees and estimated US$70k expenses) NTBV would improve to approximately US$40.7 million, or US$0.18 per share, implying immediate dilution of US$1.07 per share to new investors. Additional dilution is possible from: (i) 500k Series A and 4.54 m Series C preferred conversions; (ii) 1.14 m vested RSUs; and (iii) future financings.

Key risks disclosed include: substantial additional capital needs ahead of clinical and AI initiatives; potential constraints imposed by outstanding preferred stock and loan agreements; broad management discretion over proceeds; market overhang from continuous ATM issuance; and the possibility that financing may not be available on acceptable terms, jeopardising ongoing operations.

Strategic context. The facility provides funding flexibility without the execution risk or discount typically associated with overnight offerings, yet continuous issuance could pressure the share price given average trading volumes and the relatively low US$1.25 stock price. Operational execution in advancing TVGN 489 and other pipeline assets remains critical to justify ongoing dilution.

Form 144 filing overview: The notice discloses a proposed sale of 1,351 Class A common shares of the issuer (symbol XYZ) through broker Morgan Stanley Smith Barney on the NYSE around 02 July 2025. At the indicated market price, the transaction is valued at approximately US$93,571.

Context of prior sales: The same beneficial owner, identified as Amrita Ahuja, reported two earlier open-market sales within the last three months:

• 20 May 2025: 10,002 shares sold for gross proceeds of US$564,009
• 02 Apr 2025: 1,976 shares sold for gross proceeds of US$111,031

Materiality: The upcoming 1,351-share sale represents just about 0.00024 % of the issuer鈥檚 stated 555,001,000 shares outstanding, suggesting an immaterial impact on share-count and voting power. Nevertheless, investors often monitor insider activity for sentiment signals rather than dilution risk.

Regulatory assertions: By signing the Form 144, the seller certifies that no undisclosed material adverse information is known and that any Rule 10b5-1 trading plan (if applicable) was adopted in good faith.

Rhythm Pharmaceuticals (RYTM) 鈥� insider Form 4 filing

Chief Scientific Officer Alastair Garfield settled 4,445 restricted stock units on 1-Jul-2025, receiving an equal number of common shares. On 2-Jul-2025 he sold 1,319 of those shares in two trades at prices of $64.81 and $64.60 under a pre-arranged Rule 10b5-1 plan adopted 25-Jun-2024, with the stated purpose of covering withholding taxes. After the transactions he retains 3,126 directly held shares and 13,333 unvested RSUs that vest 25 % annually through 1-Jul-2028, subject to continued employment. No other equity instruments were created or disposed of. Given the modest size of the sale relative to Rhythm鈥檚 share count and its tax-related rationale, the event is viewed as routine compensation management with limited signaling value for investors.

Form 4 highlights for Enstar Group Limited (ESGR)

Chief Accounting Officer Girish Ramanathan has reported the disposition of 1,861 ordinary shares on 2 July 2025 at a cash value of $338 per share. The transaction coincides with the closing of the previously announced merger whereby Sixth Street Partners, LLC indirectly acquired Enstar Group pursuant to the Agreement and Plan of Merger dated 29 July 2024.

Per the merger terms, every outstanding Enstar ordinary share was cancelled and converted into the right to receive the same $338 cash consideration (before taxes). As a result, the reporting person鈥檚 direct equity stake in Enstar fell to zero shares.

The filing also details the treatment of equity awards:

• 753 Restricted Share Units (RSUs) held by the insider fully vested, were cancelled, and converted into the cash merger consideration.
• 520 unvested RSUs granted 20 Mar 2025 were converted into a cash-settled award that will vest in three equal annual tranches beginning 20 Mar 2026.

No derivative securities remain outstanding for the insider, and the form is filed as an individual filing (Box 6 checked).

The disclosure confirms final consummation of the merger and provides transparency on insider equity conversion, signaling that ordinary shares are no longer outstanding and investors will receive cash proceeds of $338 per share.

Clover Health Investments (CLOV) 鈥� Form 4 insider filing: CEO and Director Andrew Toy reported an automatic share disposition on 07/01/2025 related to the vesting of previously granted RSUs. A total of 308,950 Class A common shares were withheld to satisfy tax obligations (transaction code 鈥淔鈥�) at a reference price of $2.75. Following the withholding, Toy鈥檚 direct beneficial ownership stands at 10,560,047 shares. The RSU award, originally granted on 01/01/2023 and reported on 01/04/2023, vests quarterly in equal 6.25% installments through 01/01/2027, contingent upon continued service.

The filing reflects a routine, non-open-market administrative transaction rather than an elective sale, and does not indicate a change in Toy鈥檚 long-term ownership intent. No derivative securities or additional open-market trades were reported.

Dollar Tree Chief Supply Chain Officer Roxanne Rena Weng received 5,539 restricted stock units (RSUs) on May 30, 2025, as reported in a Form 4 filing. The RSUs were granted under the company's 2021 Omnibus Incentive Plan at a price of $0.

Key details of the grant:

• The RSUs will vest in three approximately equal annual installments
• Vesting begins on the anniversary of the award date
• Vesting is subject to continued employment
• The securities are held in direct ownership

This equity compensation grant aligns the executive's interests with shareholders and serves as a retention tool through its three-year vesting schedule. The transaction was reported within the required SEC filing deadline, with the Form 4 being filed on June 28, 2025.

Dollar Tree Chief Information Officer Robert Aflatooni reported a sale of 175 shares of common stock on June 20, 2025, at a price of $97.54 per share, totaling approximately $17,069.50.

Following the transaction, Aflatooni continues to hold 23,205 shares directly. The sale was reported through Form 4 filed on June 28, 2025, and was executed as a direct ownership transaction. The filing was signed by John S. Mitchell, Jr., acting as attorney-in-fact for Mr. Aflatooni.

This insider sale represents a relatively small portion (approximately 0.75%) of Aflatooni's total holdings in Dollar Tree, suggesting this may be part of routine portfolio management rather than a significant shift in insider sentiment.

Dollar Tree, Inc. (DLTR) 鈥� Form 144 filing indicates an affiliate鈥檚 intent to sell 3,134 common shares through broker Charles Schwab on or about 20 June 2025. At the filing鈥檚 stated market price, the shares are valued at $305,690, representing roughly 0.0015 % of Dollar Tree鈥檚 208.7 million shares outstanding.

The shares derive from equity compensation: 2,959 shares from a restricted-stock vesting and 175 shares purchased via the employee stock-purchase plan during 2023. No other sales by the filer have occurred in the past three months, and the filer affirms no possession of undisclosed material adverse information.

While the transaction provides insight into insider liquidity activity, the modest size relative to Dollar Tree鈥檚 market capitalization suggests minimal direct impact on the company鈥檚 capital structure or trading dynamics.